Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care (CIC) - Electronic Measurement of Compliance

AstraZeneca1 site in 1 country1,000 target enrollmentApril 2010

ConditionsAcute Coronary Syndrome

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Acute Coronary Syndrome
Sponsor: AstraZeneca
Enrollment: 1000
Locations: 1
Primary Endpoint: To measure, using an electronic system ("intelligent blister pack®"), the duration of treatment and number of treatment intake per day over 3 months with statin and oral antiplatelet therapy following an inaugural acute coronary syndrome.
Status: Terminated
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To study compliance with secondary prevention during the first months following discharge from the cardiac intensive care unit (CIC) of patients experiencing a first episode of acute coronary syndrome : quantitative compliance over 3 months with the two principal treatments of the prescription (a statin - rosuvastatin, Crestor® and a platelet aggregation inhibitor - clopidogrel, Plavix®), using an electronic measure system ("intelligent blister" pack®);

Registry

clinicaltrials.gov

Start Date

April 2010

End Date

March 2011

Last Updated

15 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

AstraZeneca

Eligibility Criteria

Inclusion Criteria

•Patient admitted to the CIC unit for a first episode of acute coronary syndrome, in whom the CIC cardiologist considers that Crestor® -rosuvastatin is the most appropriate statin, in combination with a platelet aggregation inhibitor (Plavix®-clopidogrel)
•Patient giving his/her oral consent to participate in the study.
•Patient not previously treated by a lipid-lowering drug.

Exclusion Criteria

•Patient with a known history of coronary heart disease.
•Patient whose treatment on discharge comprises only one of the two study treatments
•Patient participating or who has participated in the previous 3 months in a biomedical research study in cardiology.

Outcomes

Primary Outcomes

To measure, using an electronic system ("intelligent blister pack®"), the duration of treatment and number of treatment intake per day over 3 months with statin and oral antiplatelet therapy following an inaugural acute coronary syndrome.

Time Frame: 3 months / every day

Secondary Outcomes

Analysis of the duration of treatment and number of treatment intake per day at 1 month and 2 months with a statin and a platelet aggregation inhibitor, using an electronic system ("intelligent blister pack®").(1 and 2 months / every day)
Describe global compliance with the entire prescription over 6 months(6 months / Once at 6 months follow-up)
Determine the factors influencing compliance with treatment on discharge from CIC (discharge treatment including a statin - rosuvastatin, Crestor® and a platelet aggregation inhibitor - clopidogrel, Plavix®).(6 months)